UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5102-TPS5102

2023

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14576-e14576

2019

Link zum Volltext

Verfügbarkeit prüfen

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS524-TPS524

2024

Link zum Volltext

Verfügbarkeit prüfen

What do oncologists think patients with incurable cancer should be told about their prognosis? A survey of medical oncologists in Australia and New Zealand

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e22139-e22139

2018

Link zum Volltext

Verfügbarkeit prüfen

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)

Journal of clinical oncology, 2022-06, Vol.40 (17_suppl), p.LBA5004-LBA5004

2022

Link zum Volltext

Verfügbarkeit prüfen

Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS367-TPS367

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of efficacy and tolerability of weekly adjuvant chemotherapy for colorectal cancer (CRC) using folinic acid with fluorouracil dosed at 425 mg/m 2 or 370 mg/m 2

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15134-e15134

2016

Link zum Volltext

Verfügbarkeit prüfen

TheraP: A randomized phase II trial of [ 177 Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS332-TPS332

2019

Link zum Volltext

Verfügbarkeit prüfen

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS539-TPS539

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS5096-TPS5096

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer

JNCI cancer spectrum, 2018-10, Vol.2 (4), p.pky037-pky037

2018

Link zum Volltext

Verfügbarkeit prüfen

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS4596-TPS4596

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS156-TPS156

2018

Link zum Volltext

Verfügbarkeit prüfen

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS574-TPS574

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5090-TPS5090

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5086-TPS5086

2016

Link zum Volltext

Verfügbarkeit prüfen

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS4592-TPS4592

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16056-e16056

2016

Link zum Volltext

Verfügbarkeit prüfen

Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.404-404

2015

Link zum Volltext

Verfügbarkeit prüfen

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

The New England journal of medicine, 2023-04, Vol.388 (17), p.1547-1558

2023

Link zum Volltext

Verfügbarkeit prüfen

Essential medicines for cancer: WHO recommendations and national priorities

Bulletin of the World Health Organization, 2016-10, Vol.94 (10), p.735-742

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis

Cochrane database of systematic reviews, 2019-09, Vol.9 (9), p.CD013103-CD013103

2019

Link zum Volltext

Verfügbarkeit prüfen

Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis

Cochrane database of systematic reviews, 2021-06, Vol.6 (6), p.CD013156-CD013156

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(66)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(39)
Humans
(35)
General & Internal Medicine
(17)
Male
(17)
Medicine, General & Internal
(14)
Middle Aged
(14)
Aged
(11)
Female
(11)
Medicin Och Hälsovetenskap
(11)
Patients
(11)
Oncology
(8)
Prostate Cancer
(8)
Randomized Controlled Trials As Topic
(8)
Treatment Outcome
(8)
Adult
(7)
Gastroenterology & Hepatology
(7)
Liver Disorders
(7)
Medicine General & Introductory Medical Sciences
(7)
Network Meta-Analysis
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)

What do oncologists think patients with incurable cancer should be told about their prognosis? A survey of medical oncologists in Australia and New Zealand

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)

Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601)

Comparison of efficacy and tolerability of weekly adjuvant chemotherapy for colorectal cancer (CRC) using folinic acid with fluorouracil dosed at 425 mg/m 2 or 370 mg/m 2

TheraP: A randomized phase II trial of [ 177 Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303)

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial

Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

Essential medicines for cancer: WHO recommendations and national priorities

Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis

Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis

Suchergebnisse filtern